Sanofi Healthcare India receives marketing authorization for Rezurock, a new treatment for chronic graft-versus-host disease ...

Sanofi Healthcare India has obtained marketing authorization for Rezurock, a drug for treating Chronic graft versus host ...

Sanofi Healthcare India receives marketing authorization for Rezurock (Belumosudil), a new treatment for Chronic Graft-versus-Host Disease (cGVHD) in adults and adolescents.

Saudi Arabia is now shifting toward localized production, a move that will significantly enhance national drug security and ...

The Indian subsidiary of French pharma major Sanofi has received marketing authorization for Rezurock (belumosudil tablets) in India.

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Sanofi Healthcare India has received marketing authorization for Rezurock, a drug for chronic graft versus host disease (cGVHD). Approved by USFDA and CDSCO, Rezurock offers a new treatment for ...

The US FDA has warned Sanofi about significant deviations from Current Good Manufacturing Practice for active pharmaceutical ingredients.

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

We recently compiled a list of the 12 Best International Dividend Stocks To Buy Now. In this article, we are going to take a ...

Amazon Music and WPP unveiled Louder Than Cancer, an effort uniting top global artists to harness the power of music in recognition of World Cancer Day with creative leadership from WPP’s Grey Health, ...